STL Index for: systemic therapy

The discussed cases reflect the panels’ real-world clinical experience with crisaborole for the treatment of patients with AD and the off-label treatment of irritant dermatitis.

A list of skin treatments introduced in 2018, categorized by type/class of therapy. The content primarily focuses on approvals issued by US and Canadian drug regulatory agencies and is sourced from both regulatory and industry news releases.

Evolving understanding of the role of hormones in acne, along with a growing body of data from clinical trials, calls for a reappraisal of the role of hormonal therapy for acne.

A look back at skin treatments introduced in 2017 for the following type/class of therapy: Antibiotic agents, anti-cancer agents, atopic dermatitis, dermal fillers, fabry disease, hereditary angioedema, herpes zoster, hidradenitis suppurativa, psoriasis, psoriatic arthritis, rosacea...

Update on drugs includes Onabotulinum-toxinA for injection (Botox® Cosmetic), Hyaluronic acid dermal filler (Restylane® Silk), Ustekinumab for SC injection (Stelara®), Golimumab for IV infusion (RSimponi Aria®), Herpes zoster vaccine (non-live recombinant, AS01B adjuvanted) suspension for IM injection (Shingrix), Brentuximab vedotin for IV infusion (Adcetris®)

Atopic dermatitis (AD) is a chronic, relapsing, pruritic, inflammatory condition involving the skin which can have a significant impact on the quality of life. This article will guide the family practitioner on how to manage adults with moderate-to-severe AD and when to refer for specialist management.

Tofacitinib is an oral immunosuppressant approved for the treatment of rheumatoid arthritis (RA) and is currently undergoing investigation (Phase III trials) for treating chronic plaque psoriasis.

The list covers new skin treatments for Actinic Keratosis, Hemangioma, Hidradenitis Suppurativa, as well as Anti-acne Agents, Antibacterial Agents, Anti-cancer Agents, Dermal Fillers, Neuromodulator and other treatments and drugs.

Onychomycosis is a stubborn fungal infection of the nails that can be difficult to manage. Clinical trial data of Tavaborole is considered, as it allows for effective nail penetration compared to ciclopirox and amorolfine lacquers.

Autoimmune blistering diseases are rare, but potentially debilitating characterized by varying degrees of mucosal and cutaneous bullae formation. This article discusses individually tailored treatment, diagnosis, severity, comorbidities, and tolerance for systemic therapy.

This article discusses the role that dermatologists can play in recognizing the cutaneous manifestations linked with some systemic conditions. Identifying the underlying disorder will contribute to appropriate diagnosis and improved management.

This article reviews the various subtypes of rosacea, their clinical presentations, and the considerations in choosing the optimal therapeutic options. The importance of tailored treatment is discussed as well as topical therapies.

Many options exist for the treatment of rosacea, including topical and systemic therapies, laser and light-based therapies, and surgical procedures. The goals of therapy include reduction of papules, pustules, erythema, physical discomfort, and an improvement in quality of life.

Onychomycosis is one of the most common nail disorders. Despite recent therapeutic advances with the introduction of effective systemic agents and transungual drug delivery systems, the incidence of onychomycosis is increasing.

Penlac (Ciclopirox), and its pharmacokinetics, delivery system, safety, and patient selection are discussed. Monotherapy and combination therapy and its patient criteria are discussed.

Rosacea is a common condition that affects people of all races. More aggressive and innovative uses of existing oral agents have resulted in novel therapeutic approaches, which can provide long-term therapy and sustained remission.

Amevive (Alefacept), clinical experience, patient profiles, indications, dosing and cost are discussed in this article.

Educate and counsel. Most patients with acne are teenagers who are very self-conscious about their looks and expect immediate treatment results. However, adult acne is becoming more common, and can be very distressing as well.

Onychomycosis is a common disease, and there are a number of factors that may affect the duration and dosage of treatment including the type of onychomycosis, the area and thickness of nail involvement, the age of the patient, and the location of the digit that is affected.

If methotrexate were introduced as a new drug today, it would be hailed as a major advance in the management of psoriasis, as well as for a number of other conditions. When patients are properly screened and educated about the correct use of this drug, and appropriately monitored during treatment, MTX is often very safe, simple to use, inexpensive, and well-tolerated.